BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
92.80
-0.87 (-0.93%)
At close: Aug 10, 2026, 4:00 PM EDT
93.37
+0.57 (0.61%)
Pre-market: Aug 11, 2026, 8:21 AM EDT
BioNTech SE Revenue
BioNTech SE had revenue of 145.80M EUR in the quarter ending June 30, 2026, a decrease of -56.99%. This brings the company's revenue in the last twelve months to 2.43B, down -0.35% year-over-year. In the year 2025, BioNTech SE had annual revenue of 3.05B with 5.63% growth.
Revenue (ttm)
2.43B EUR
Revenue Growth
-0.35%
P/S Ratio
7.70
Revenue / Employee
310,785 EUR
Employees
7,807
Market Cap
23.31B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.05B | 162.80M | 5.63% |
| Dec 31, 2024 | 2.89B | -1.03B | -26.31% |
| Dec 31, 2023 | 3.92B | -13.39B | -77.33% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
| Dec 31, 2018 | 127.58M | 65.98M | 107.11% |
| Dec 31, 2017 | 61.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| Alnylam Pharmaceuticals | 4.80B |
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| Royalty Pharma | 2.54B |
| Moderna | 2.23B |
| Insmed | 1.14B |
BNTX News
- 5 days ago - BioNTech price target lowered to $130 from $135 at Evercore ISI - TheFly
- 6 days ago - BioNTech price target raised to $142 from $138 at Canaccord - TheFly
- 6 days ago - BioNTech price target lowered to $125 from $130 at Citi - TheFly
- 7 days ago - BioNTech SE Earnings Call Transcript: Q2 2026 - Transcripts
- 7 days ago - BioNTech SE Earnings release: Q2 2026 - Filings
- 7 days ago - BioNTech SE Slides: Q2 2026 - Filings
- 7 days ago - Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings - Barrons
- 7 days ago - BioNTech lowers 2026 sales outlook as COVID vaccine demand softens - Reuters